Research supported by Knight Initiative for Brain Resilience grants and fellowships is advancing our understanding of healthy brain aging and new approaches to combat neurodegenerative disease.
Donanemab slows symptoms of Alzheimer's, but its long-term effects are uncertain. Kathleen Poston, a Knight Initiative steering committee member, emphasizes the need for scientists to obtain data to extrapolate these findings to everyone with AD.
